PICALM is a highly validated genetic risk factor for Alzheimer's disease (AD). We found that reduced expression of PICALM in AD and murine brain endothelium correlated with amyloid- (A) pathology and cognitive impairment. Moreover, Picalm deficiency diminished A clearance across the murine blood-brain barrier (BBB) and accelerated A pathology in a manner that was reversible by endothelial PICALM re-expression. Using human brain endothelial monolayers, we found that PICALM regulated PICALM/clathrin-dependent internalization of A bound to the low density lipoprotein receptor related protein-1, a key A clearance receptor, and guided A trafficking to Rab5 and Rab11, leading to A endothelial transcytosis and clearance. PICALM levels and A clearance were reduced in AD-derived endothelial monolayers, which was reversible by adenoviral-mediated PICALM transfer. Inducible pluripotent stem cell-derived human endothelial cells carrying the rs3851179 protective allele exhibited higher PICALM levels and enhanced A clearance. Thus, PICALM regulates A BBB transcytosis and clearance, which has implications for A brain homeostasis and clearance therapy. npg 9 7 9 a r t I C l e S Microvessels PICALM GAPDH Control AD vWF β3-tubulin GFAP Microvesseldepleted brain 75 250 50 50 40 kDa Control AD b PICALM Amyloid β AD (Braak V-VI) Control (Braak I) a 0 0.5 1.0 1.5 2.0 Control AD
a r t I C l e S PICALM, the gene encoding the phosphatidylinositol-binding clathrin assembly (PICALM) protein 1, 2 , is important for endocytosis and internalization of cell receptors [3] [4] [5] [6] . PICALM also mediates intracellular trafficking of endocytic proteins 7, 8 . Several genomewide association studies have shown the association of PICALM with AD 9-13 , a neurological disorder characterized by neurovascular dysfunction, elevated Aβ, tau pathology and neuronal loss [14] [15] [16] . However, the role of PICALM in disease pathogenesis remains elusive.
PICALM was originally postulated to affect disease by modifying trafficking of Aβ precursor protein (APP) 9 . Recent studies suggested that PICALM protects neurons from Aβ toxicity by reversing Aβ effects on clathrin-mediated endocytosis 6 and/or by directing APP transport to the terminal degradation pathway by autophagosomes, which reduces Aβ production 17 . In contrast, viral-mediated silencing of PICALM in the hippocampal neurons in APP-overexpressing mice has been shown to diminish Aβ production, resulting in a moderate reduction in Aβ load 18 . Furthermore, PICALM influences the ratio of Aβ42 to total Aβ in neurons through clathrin-mediated endocytosis of γ-secretase 19 .
In addition to its neuronal functionality, PICALM is abundantly expressed in brain capillary endothelium 20, 21 , a site of the BBB in vivo 14 , which provides a major pathway for Aβ clearance from the brain into circulation 14, 22, 23 . Thus, PICALM is ideally situated to regulate the function of brain capillary endothelial receptors, including receptors that mediate Aβ clearance such as the lowdensity lipoprotein receptor related protein 1 (LRP1), which binds Aβ and is a key Aβ clearance receptor at the BBB and vascular cells [22] [23] [24] [25] [26] [27] . Thus, we hypothesized that PICALM influences Aβ clearance across the BBB and, at the molecular level, regulates the function of LRP1 in brain endothelial cells [22] [23] [24] . Our data suggest that endothelial PICALM has a central role in Aβ clearance and transcytosis across the BBB, which is critical for regulation of Aβ levels and homeostasis in the brain.
RESULTS

PICALM reductions in brain endothelium in AD
We found robust expression of PICALM in microvessels in aged control human brains without dementia by immunocytochemistry ( Fig. 1a) , immunoblotting (Fig. 1b,c) and double fluorescence immunostaining for PICALM and endothelial-specific Lycopersicon esculentum lectin ( Fig. 1d and Supplementary Fig. 1a) , indicating that ~65% of the endothelial cell surface area labeled with lectin was positive for PICALM in the hippocampus and cortex (Fig. 1e) . PICALM levels in isolated cortical microvessels from control human brains were more than 1.7-fold , β3-tubulin, glial fibrillar acidic protein (GFAP) and GAPDH (loading control) in isolated microvessels and microvessel-depleted brains from controls (Braak 0-I) and AD cases (Braak V-VI). (c) Relative abundance of PICALM in microvessels and microvessel-depleted brains from control and AD cases determined by densitometry analysis relative to GAPDH. Data are presented as mean ± s.e.m., n = 6 cases per group; P < 0.05 by ANOVA followed by Tukey's post hoc tests. (d) PICALM (green), lectin-positive endothelial capillary profiles (magenta) and MAP2-positive neurons (red) in the hippocampus (CA1) of an age-matched control (Braak I) and AD cases (Braak III and V-VI). Scale bar represents 20 µm. (e) Quantification of PICALM-positive area (percentage) occupying lectin-positive endothelial capillary profiles in the prefrontal cortex (Ctx) and the CA1 hippocampal subfield (Hpc). Data are presented as mean ± s.d., n = 9 controls (Braak 0-I) and 7 AD cases (Braak V-VI); P < 0.01 by Student's t test. (f-i) Correlations between PICALMpositive area occupying lectin-positive endothelial capillary profiles (percentage) in the prefrontal cortex and Aβ load (f), Braak stages (g), Clinical Dementia Rating (CDR, h) and Mini-Mental State Examination (MMSE, i). Each point in f-i is an individual value from 50 (f,g), 28 (h) and 37 (i) controls and AD cases. CDR and MMSE were not available for all cases. Significance was determined by Pearson and Spearman rank correlation analysis.
higher than in capillary-depleted brain homogenates containing neurons and glia (Fig. 1b,c) . In advanced AD (Braak stage V-VI), compared with controls (Braak stage I), PICALM levels were reduced in cerebral microvessels ( Fig. 1a,b,d and Supplementary Fig. 1a ) by 55-65%, as shown by immunoblotting ( Fig. 1c ) and double staining for PICALM and lectin, respectively ( Fig. 1e) . In contrast, immunostaining for PICALM and the neuronal marker microtubule-associated protein 2 (MAP2) revealed a moderate increase in PICALM levels in neurons in advanced AD (Braak V-VI) compared with controls ( Fig. 1d) , consistent with a previous report 28 . When comparing 30 AD cases (Braak stage III-IV and V-VI) with 20 controls (Braak stage 0-I to III) ( Supplementary Table 1a ), we found that PICALM endothelial levels inversely correlated with Aβ load (Fig. 1f) , Braak stage ( Fig. 1g ) and clinical dementia rating (Fig. 1h) , and positively correlated with mini-mental state exam scores ( Fig. 1i) . As in humans, PICALM levels in murine brain microvessels were more than twofold higher than in capillary-depleted brain homogenates ( Supplementary Fig. 1b) . Notably, elevated Aβ levels in APP-overexpressing APP Sw/0 mice 29 or in endothelial cultures did not affect PICALM levels ( Supplementary  Fig. 1c-e ), ruling out Aβ as a PICALM suppressor. Thus, endothelial loss of PICALM in AD is associated with greater Aβ and AD pathology and worse cognitive impairment.
Diminished Ab clearance in Picalm +/− mice To address whether PICALM is involved in Aβ clearance across the BBB in vivo and whether it contributes to worsening AD pathology, we next studied clearance of human Aβ40 and Aβ42 in Picalm +/− mice (generated as shown in Supplementary Fig. 2a ). Complete knockout of Picalm was embryonic lethal, but Picalm +/− mice developed normally and had normal blood glucose, hepatic and renal analyses ( Supplementary Fig. 2b-m) and did not show behavioral changes in the first 9 months ( Supplementary Fig. 2n-q) . Compared with their npg a r t I C l e S littermate controls, Picalm +/− mice had ~70% lower levels of PICALM in brain microvessels and ~50% reduction in PICALM in capillarydepleted brain ( Fig. 2a,b) . Using an Aβ clearance assay 22, 23 and ELISA 27 , we found that 3-month-old Picalm +/− mice have 38% and 36% greater brain retention of Aβ40 and Aβ42, respectively, 30 min after intracerebral administration of human Aβ40 or Aβ42 (1 ng) than controls ( Fig. 2c) . There was no difference in retention of inulin, an inert extracellular space marker frequently used to estimate brain interstitial fluid (ISF)-to-cerebrospinal fluid (CSF) bulk flow 22, 23 (Fig. 2c) . Consistent with these results, Picalm deficiency diminished Aβ40 and Aβ42 efflux across the BBB by 41% and 61%, respectively ( Fig. 2d and Online Methods), but did not affect Aβ efflux via ISF compared with controls ( Fig. 2e) . We found 48% and 65% lower plasma levels of Aβ40 and Aβ42, respectively, in Picalm +/− mice compared with control Picalm +/+ mice ( Fig. 2f) , confirming impaired Aβ clearance from brain to blood. (e,f) Representative hippocampus and cortex sections stained with human Aβ-specific antibodies in 9-month-old APP sw/0 ; Picalm +/+ and APP sw/0 ; Picalm +/− mice showing accelerated Aβ deposition (e) and increased Aβ load (f). In a-c and f, data are presented as means ± s.e.m., n = 5-6 mice per group. Scale bar represents 100 µm. (g-i) Behavioral changes in 9-month-old APP sw/0 ; Picalm +/+ and APP sw/0 ; Picalm +/− mice studied by nest construction (g), burrowing (h), novel object location (NOL) and novel object recognition (NOR) (i). Data are presented as means ± s.e.m. n = 12-14 mice per group. In g-i, statistical significance was determined by Student's t test. In i, boxplots represent the median (dark horizontal line), with the box representing the 25th and 75th percentiles, and the whiskers the 5th and 95th percentile. npg a r t I C l e S Effects of Picalm deficiency and endothelial-specific rescue in APP sw/0 mice To address whether Picalm deficiency can influence Aβ pathology, we crossed transgenic APP sw/0 mice, which develop Aβ elevation and correlative memory deficits 29 , with Picalm +/− mice. PICALM expression in APP sw/0 ; Picalm +/− mice was reduced by ~70% in microvessels and ~50% in capillary-depleted brain compared with their littermate controls ( Supplementary Fig. 3a,b ). Using hippocampal in vivo microdialysis 27 (Online Methods), we found a substantial 2.4-and 2.5-fold increase in the steady-state levels of soluble Aβ40 and Aβ42 in brain ISF of 3-month-old APP sw/0 ; Picalm +/− mice compared with age-matched littermate controls, respectively ( Fig. 3a,b) . After intraperitoneal injection of the γ-secretase inhibitor Compound E, the half-life of Aβ40 and Aβ42 in brain ISF 27 was increased in APP sw/0 ; Picalm +/− mice compared with APP sw/0 ; Picalm +/− controls from 1.2 to 1.9 h and 1.4 to 2.5 h, respectively ( Fig. 3c) , suggesting that the increase of ISF Aβ levels was a result of diminished Aβ clearance. The increase in Aβ ISF levels preceded Aβ and amyloid deposition. Deposits were absent in 3-month-old APP sw/0 ; Picalm +/− mice ( Fig. 3d) , but began to accumulate at 6 months of age, as shown by the increase in Aβ load in the hippocampus and cortex and accelerated development of cerebral amyloid angiopathy ( Supplementary  Fig. 3c,d) . Notably, 9-month-old APP sw/0 ; Picalm +/− mice had a substantial 3.5-4-fold increase in Aβ load in the cortex and hippocampus ( Fig. 3e,f) , which was associated with worse performance in behavioral tests, including nest construction, burrowing, novel object location and novel object recognition ( Fig. 3g-i) , compared with age-matched littermate controls.
To specifically address the role of endothelial PICALM in transvascular Aβ clearance, we performed a rescue experiment. We generated APP sw/0 ; Picalm +/− ; Tie2-Cre mice and an adeno-associated viral (AAV)-Flex-Picalm construct for delivery of a Cre-dependent expression cassette (Flex-Picalm) specifically to brain endothelium in the hippocampus (Fig. 4a) . After administration of AAV-Flex-Tdtomato into the hippocampus of 5-month-old APP sw/0 ; Picalm +/− ; Tie2-Cre mice, more than 50% of lectin-positive endothelial vascular profiles expressed Tie2-Cre-dependent Tdtomato ( Supplementary  Fig. 4a ). Co-injection of AAV-Flex-Tdtomato and AAV-Syn1-GFP revealed that less than 3% of hippocampal neurons expressed Tdtomato. Together, these data confirm Tie2-Cre-dependent endothelial-specific expression of transgene and minimal leakage in neurons. Similar results were obtained after administration of AAV-Flex-Picalm into the hippocampus of 5-month-old APP sw/0 ; Picalm +/− ; Tie2-Cre mice with Tie2-Cre-dependent Flag-PICALM expression in more than 50% lectin-positive endothelial vascular profiles, and we observed negligible expression in neurons after co-injection of AAV-Flex-Picalm and AAV-Syn1-GFP (Fig. 4b) .
PICALM re-expression in endothelium of APP sw/0 ; Picalm +/− ;Tie2-Cre mice after AAV-Flex-Picalm administration in the ipsilateral hippocampus diminished Aβ load, Aβ40 and Aβ42 levels by 63%, 46% and 37%, respectively, compared with the contralateral hippocampus injected with AAV-Flex (control) virus ( Fig. 4c-e and Supplementary Fig. 4b) .
Moreover, bilateral administration of AAV-Flex-Picalm in the left and right hippocampus improved behavior in APP sw/0 ; Picalm +/− ;Tie2-Cre mice compared with AAV-Flex (control), as shown in a separate group of mice ( Fig. 4f,g) . These data strongly support our hypothesis that brain endothelial PICALM has a central role in regulating Aβ clearance from the brain by controlling its efflux at the BBB.
Neither Picalm +/− nor APP sw/0 ; Picalm +/− mice showed changes in Aβ production and processing 15, 16 , brain microvascular expression of a r t I C l e S major Aβ transporters, including P-glycoprotein, LRP1 and RAGE 14 , or Aβ-degrading enzymes, including neprilysin and insulin-degrading enzyme 16 , compared with their respective controls ( Supplementary  Fig. 5 ), which make these mechanisms unlikely contributors to decreased Aβ clearance and/or increased Aβ accumulation.
PICALM/clathrin-dependent endocytosis of Ab-LRP1 complex by endothelial cells
To elucidate the molecular mechanism(s) underlying PICALM regulation of Aβ clearance across the BBB, we studied Aβ internalization and trafficking in primary human brain endothelial cells (BECs) and in an in vitro model of the BBB 30 . We found that Aβ40 bound to the cell surface LRP1 in BECs at 4 °C, as reported previously 14, 23 ( Supplementary Fig. 6a , Supplementary Table 1 and Online Methods), and that 6-carboxyfluorescein-labeled (FAM)-Aβ40-LRP1 complex colocalized rapidly (≤30 s) with PICALM ( Fig. 5a ) and proteins responsible for PICALM/clathrin-dependent internalization of ligands 2,5 at 37 °C, including the clathrin heavy chain (CHC; Fig. 5b-d) and clathrin adaptor protein α-adaptin (AP-2; Supplementary Fig. 6b ). Similar to Aβ40, FAM-Aβ42, but not scrambled FAM-Aβ42 (Supplementary Fig. 6c,d) , led to a rapid increase in colocalized Aβ-LRP1/PICALM puncta. Rapid recruitment a r t I C l e S of PICALM and the clathrin endocytotic apparatus to LRP1 was confirmed by co-immunoprecipitation analysis 30 s after Aβ40 treatment at 1 nM, a concentration corresponding to Aβ40 levels in the CSF 14, 16 (Fig. 5e) . In contrast with PICALM, which remains associated with LRP1 over longer periods of time, CHC and AP-2 dissociated early from LRP1 (Fig. 5e) , consistent with rapid uncoating of clathrin from internalized vesicles 5 . siRNA inhibition of PICALM or CHC inhibited Aβ40-induced LRP1 internalization ( Fig. 5f) , suggesting that endocytosis of Aβ-LRP1 complex requires both PICALM and clathrin.
To further understand PICALM interaction with LRP1, we studied binding of human recombinant PICALM to a human recombinant glutathione S-transferase (GST)-tagged LRP1 C-terminus fusion protein, which indicated direct binding of PICALM to LRP1 C terminus (Fig. 5g) , but not to GST (Supplementary Fig. 6e ). Although this experiment was carried out in the absence of cells, we cannot rule out the possibility that some intermediary proteins in the cellular milieu can facilitate and/or influence PICALM binding to LRP1. Using co-immunoprecipitation analysis after transfection of cells with PICALM and various mutants of the C-terminus LRP1 cytoplasmic tail 31 , we found that PICALM binding to LRP1 required the YXXL motif ( Fig. 5h,i) .
To determine the specificity of Aβ as a ligand that enhances the binding of PICALM to the cytoplasmic tail of LRP1, we studied other LRP1 ligands, including apolipoprotein E (apoE) and activated α2-macroglobulin (α2M*). Incubation of BECs with astrocytederived lipidated apoE3, apoE4 (ref. 32 ) and α2M* did not result in a rapid binding of PICALM to LRP1, whereas Aβ40 binding to apoE3, apoE4 and α2M* inhibited PICALM binding to LRP1 (Supplementary Fig. 7a ). Consistent with these data, binding of Aβ40 to apoE4, apoE3 and α2M* inhibited Aβ40-induced internalization of LRP1 (Supplementary Fig. 7b,c) . Collectively, these data suggest that binding of Aβ to the ectodomain of LRP1 has a unique conformational effect on its cytoplasmatic C-terminus tail, enhancing the binding of PICALM, which initiates PICALM/clathrin-dependent endocytosis of Aβ-LRP1 complex.
PICALM associates with LRP1 during Ab transcytosis across an endothelial monolayer
We next used an in vitro model of the BBB 30 to study the role of PICALM in Aβ transport across fully confluent (>97%) human brain endothelial monolayer co-cultured with pericyte-conditioned medium, as pericytes critically influence the BBB properties [33] [34] [35] . The endothelial monolayer had a typical cobblestone pattern of the zonula occludens 1 (ZO-1) tight junction protein and a cortical distribution of the F-actin cytoskeleton and expressed PICALM (Fig. 6a) . A transmonolayer electrical resistance (TEER) of ~280 Ω cm 2 and a low paracellular permeability constant (P) of ~1.21 × 10 −6 cm s −1 determined for dextran (molecular weight, 40 kDa), a metabolically inert polar molecule, confirmed formation of the barrier.
To ascertain whether our endothelial monolayer model is suitable for Aβ transport studies, we determined cell polarity for two key Aβ transporters, LRP1 and the receptor for advanced glycation end products (RAGE), which are expressed in brain endothelium in vivo mainly at the abluminal (basolateral) and luminal (apical) side, respectively 14 , as confirmed by signal intensity profile analysis across capillary lumens in human brain ( Supplementary Fig. 8a,b) . Consistent with in vivo findings, LRP1 and RAGE chiefly colocalized toward the basolateral and apical membrane of the endothelial monolayer, respectively (Supplementary Fig. 8c ). PICALM associated with LRP1-Aβ40 complex in the endothelial monolayer rapidly after Aβ application to the basolateral membrane ( Fig. 6b) , as it did in BEC cultures ( Fig. 5a,d,e ).
The proximity ligation assay (PLA) 32, 36 confirmed that PICALM associates rapidly with LRP1 in the endothelial monolayer after Aβ40 (1 nM) addition to the basolateral membrane with a peak at 30 s and a plateau over 4 min (Fig. 6c,d) . In contrast, LRP1-clathrin association peaked in 30 s and was followed by a sharp decline in 1 min (Fig. 6d) , consistent with co-immunoprecipitation data showing rapid dissociation of clatrhin from internalized LRP1 (Fig. 5e) .
To further study the roles of LRP1, PICALM and CHC in Aβ internalization at the basolateral endothelial membrane and the basolateral-to-apical transendothelial transport (transcytosis), we used siRNA silencing. Aβ40 (1 nM) internalization was rapid, with a t 1/2 of ~17 s (Fig. 6e) , as reported for LRP1-mediated endocytosis 31 . siRNA inhibition of LRP1, PICALM or CHC substantially diminished Aβ internalization by >90% in 1 min compared with control scrambled siRNA ( Fig. 6e) , suggesting that all three molecules are essential for Aβ internalization. Basolateral-to-apical transcytosis of Aβ40 (1 nM, determined by Aβ40 ELISA measurements in the basolateral and apical chambers corrected for paracellular diffusion by subtracting diffusion values of inulin, a metabolically inert polar molecule; Online Methods) was inhibited by the receptor-associated protein (Supplementary Fig. 9a) , confirming basolateralto-apical trans-endothelial transport.
PICALM guides Ab trafficking to Rab 5 and Rab 11 leading to Ab endothelial transcytosis Given that PICALM remains associated with LRP1 over longer periods of time in contrast to CHC and AP-2 that dissociate rapidly from internalized Aβ-LRP1 vesicles (Figs. 5e and 6d) , we next traced intracellular trafficking of PICALM and Aβ-LRP1 using molecular markers for different steps of the endosomal pathway. Because Rab5 and Rab7 regulate Aβ endosomal trafficking in neurons 37 , we asked whether PICALM interacts with Rab GTPases 38 following Aβ-LRP1 internalization. Using subconfluent endothelial cultures, we found (RAP) and LRP1-specific antibodies, but not by other low-density lipoprotein receptor-specific antibodies (Supplementary Fig. 8d ). LRP1 siRNA, but not scrambled siRNA, also inhibited Aβ40 basolateral-to-apical transendothelial transport (Supplementary Fig. 8d) . These data confirm that Aβ binding to LRP1 initiates Aβ clearance at the basolateral membrane of the monolayer, as previously suggested 14, 22, 23 , and that LRP1 is required for Aβ transcytosis across the monolayer. As expected, silencing PICALM and CHC inhibited Aβ40 transcytosis across the monolayer by approximately 85%, as shown within 30 min of the unidirectional basolateral-to-apical transendothelial Aβ transport (Fig. 6f,g) . Within 5 min of Aβ application to the basolateral membrane of the endothelial monolayer, Aβ-LRP1 internalized complex was already found near the apical membrane npg a r t I C l e S that PICALM and Aβ40-LRP1 complex colocalize with Rab5and EEA1-positive early endosomes 5 within 2 min of Aβ40 (1 nM) treatment ( Fig. 7a and Supplementary Fig. 10a,b) , but not with Rab7, a GTPase that directs fusion of late endosomes with lysosomes 38 leading to degradation of ligands 39 (Fig. 7b) or the lysosomal-specific marker LAMP1 (Supplementary Fig. 10c ) 38 . Rather, PICALM colocalized with Rab11 (Fig. 7c) , a GTPase that regulates recycling of vesicles controlling transcytosis [40] [41] [42] and exocytosis 43 of ligands. Aβ42 also colocalized with Rab5 and Rab11 ( Supplementary  Fig. 11a,b) . In the absence of Aβ, PICALM minimally colocalized with Rab5, Rab7 and/or Rab11 (Supplementary Fig. 11c-e) . These data suggest that PICALM likely regulates trans-endothelial Aβ trafficking by shunting Aβ away from a degradation pathway toward a transcytotic pathway, consistent with previously demonstrated clathrin-independent functions of PICALM 7, 8, 17 . Notably, the peak co-localization between PICALM and Rab5 (Fig. 7a,d ) was somewhat higher than the peak co-localization between PICALM and Rab11 (Fig. 7c,d) , suggesting that transfer of PICALM-containing endocytic vesicles from Rab5 to Rab11 could potentially be a rate-limiting step in Aβ transcytosis.
Using an in vitro endothelial monolayer model of the BBB, we next found that FAM-Aβ40 associated with Rab5 and Rab11 in the endothelium within 2 and 4 min of its application to the basolateral membrane, respectively (Fig. 7e,f) . PICALM-Rab11 association peaked at 4 min of incubation with Aβ40 at the basolateral membrane and remained at a plateau at 5 min (Fig. 7g,h) , whereas PICALM-Rab5 association peaked at 2 min and declined in 3-4 min (Fig. 7h) , as shown by PLA analysis. PICALM-Rab7 association was undetectable (Fig. 7h) . PICALM interaction with LRP1, Rab5 and Rab11 at different time points after Aβ40 treatment has been corroborated by co-immunoprecipitation analysis (Fig. 7i) .
Consistent with findings showing that Rab5 is necessary for the biogenesis of early and late endosomes 44 , dominant-negative Rab5-S34N mutant (Online Methods) inhibited Aβ transcytosis by more than 85% as compared with EGFP control (Fig. 7j,k) . Dominant-negative Rab11-S25N mutant, but not Rab7-T22N mutant, also inhibited unidirectional Aβ40 basolateral-to-apical transport by 75% ( Fig. 7j,k) . These data suggest that Rab11 likely controls later stages of Aβ transcytosis across the monolayer, consistent with findings showing that Rab11 regulates trafficking of vesicles controlling transcytosis [40] [41] [42] and exocytosis 43 of ligands. siRNA inhibition of Rab11b, but not Rab11a, blocked Aβ transcytosis (Supplementary Fig. 9b) , consistent with findings that Rab11b is the major Rab11 isoform in brain endothelium, whereas Rab11a is a major isoform in epithelial cells [40] [41] [42] , as we confirmed (Supplementary Fig. 9c) .
Notably, siRNA knockdown of PICALM inhibited Rab5 and Rab11 GTPase activity in the endothelial monolayers treated with Aβ40 by 80% and 95%, respectively (Fig. 7l,m) , indicating that PICALM binding to Rab5 and Rab11 is critical for maintaining Rab5 and Rab11 GTPase activity during endosomal trafficking of Aβ. Consistent with findings showing that PICALM does not direct Aβ to lysosomes for degradation, Aβ was more than 95% intact within 30 min of unidirectional transcytosis and clearance across the monolayer (Supplementary Fig. 9d) , as reported previously 23 . Collectively, our data indicate that PICALM controls the transcytotic pathway mediating Aβ clearance across the BBB.
PICALM levels and Ab clearance by endothelial monolayers from AD patients
To determine the role of PICALM in Aβ clearance in AD brain endothelium (Supplementary Table 1b) , we studied Aβ transcytosis across AD-derived endothelial monolayers co-cultured npg a r t I C l e S with pericyte-conditioned media. The AD endothelial monolayers had a normal cobblestone pattern, TEER values and paracellular permeability (Supplementary Fig. 12a-c) . Consistent with diminished PICALM levels in AD brain endothelium in situ and in brain capillaries (Fig. 1) , PICALM mRNA and protein levels were reduced by 34-35% in cultured AD BEC (Fig. 8a) , resulting in ~50% diminished basolateral-to-apical transcytosis of Aβ across AD-derived endothelial monolayers compared with age-matched controls (Fig. 8b) . LRP1 levels were also reduced in AD brain endothelium 22, 23 , whereas AP-2, CHC, Rab5 and Rab11b expression was comparable to controls (data not shown). Adenoviral-mediated transfer of PICALM compared with GFP control (Supplementary Fig. 12d ) substantially improved Aβ transcytosis by 63%, whereas co-transfer of PICALM and LRP1 mini-gene 32 improved Aβ transport by 89% ( Fig. 8b) , suggesting that PICALM can be therapeutically targeted.
Ab clearance by iPSC-derived endothelium carrying the rs3851179 PICALM variants All AD-associated single-nucleotide polymorphisms (SNPs) in PICALM are located upstream of the coding region of the gene, and no mutation in the PICALM protein has been identified to influence AD risk [9] [10] [11] [12] [13] . Some AD-associated PICALM SNPs have been suggested, however, to influence PICALM expression, for example, rs659023 variants in peripheral blood mononuclear cells 45 . To address whether certain PICALM variants can influence PICALM expression and Aβ clearance in endothelial cells, we focused on highly validated and replicated rs3851179 PICALM variants whose rs3851179 A allele is associated with a lower risk of AD than the rs3851179 G allele 9,10,12 .
To test the phenotypic differences between the minor protective rs3851179 A allele and the major non-protective rs3851179 G allele in human endothelial cells, we used inducible pluripotent stem cells (iPSCs). The iPSCs were generated from lymphoblasts from Coriell using the episomal plasmids and encoding factors as we described previously 46 . We next used CRISPR/Cas9 genome editing 47 to generate the isogenic homozygous iPSC lines for the two homozygous allelic variants ( Fig. 8c-e ) followed by direct differentiation to generate bona fide endothelial cells 48 and endothelial monolayers (Fig. 8f,g and Online Methods). iPSC-derived endothelial cells carrying the protective rs3851179 A allele had 72-78% higher expression levels of PICALM mRNA and protein ( Fig. 8h) and 120% higher Aβ clearance (Fig. 8i) than the non-protective rs3851179 G allele.
DISCUSSION
We found that PICALM reductions in brain endothelium in AD correlated with Aβ and AD neuropathology and cognitive impairment, whereas reduction and re-expression of PICALM in endothelial cells influenced Aβ clearance at the BBB, Aβ deposition in the mouse brain and phenotypic manifestations of behavior in mice. At a molecular level, using an in vitro endothelial monolayer that approximates BBB, we found that Aβ binding to the ectodomain of LRP1 enhanced the binding of PICALM, which initiated PICALM/clathrin-dependent endocytosis of Aβ-LRP1 complex, and PICALM remained associated with LRP1 after Aβ internalization and directed Aβ trafficking to Rab5 and Rab11, leading to Aβ transcytosis (Supplementary Fig. 13) . PICALM levels and Aβ clearance were greatly reduced in AD-derived endothelial monolayers, which was reversible by adenoviral-mediated PICALM transfer. Using iPSC-derived human endothelial cells carrying rs3851179 PICALM variants, we found that the protective rs3851179 allele led to a higher PICALM expression and enhanced Aβ clearance by endothelial cells.
AAV8 viral-mediated silencing of neuronal PICALM in the hippocampus moderately reduced Aβ production in APP/PS1 mice 18 , but whether a moderate reduction in Aβ load, as we observed, is beneficial for neurons after inactivation of PICALM is unclear, as PICALM also protects neurons against Aβ toxicity 6 . Mice with PICALM loss-of-function allele developed accelerated Aβ accumulation and had lower behavioral test performance than controls, raising the possibility that, in models of global Picalm deficiency, where PICALM is deleted in multiple cell populations (for example, endothelial cells, neurons), the effect of Picalm loss from endothelium causing faulty Aβ vascular clearance may override the discrepant reduction in Aβ secretion from neurons 18 . Future studies in transgenic mice with inducible PICALM deletion in neurons should be carried out to address its Aβ-independent effects, particularly as PICALM regulates axonal growth 49 and turnover of synaptic vesicles and receptors 50 .
Our data revealed that PICALM guides intracellular trafficking of Aβ-LRP1 to Rab5 and Rab11, leading to Aβ transcytosis across endothelial monolayer, which does not require clathrin beyond the early internalization steps. These findings are consistent with previously demonstrated clathrin-independent functions of PICALM in trafficking of endocytic proteins 7, 8, 17 .
At present, little is known about upstream regulators of PICALM expression. Using APP-overexpressing mice and brain endothelial cultures, we found that elevated Aβ does not suppress PICALM in endothelium. Multiple factors in AD including turbulent capillary flow, oxidant stress, hypoxia or inflammation can affect gene expression in endothelial cells 14 , potentially leading to PICALM reductions in endothelium. Identifying inhibitors of PICALM expression in AD endothelium will require future studies interrogating multiple genetic, environmental and local brain factors.
Consistent with the idea that some AD-associated PICALM SNPs may influence PICALM expression 21, 45 , using iPSCs, we found that the protective rs3851179 allele had a major effect on PICALM expression and Aβ clearance by endothelial cells. Future studies correlating PICALM levels in endothelium in human brain tissue with the genotype of patients in large cohorts of control and AD patients could provide additional information as to how different PICALM SNPs relate to each other and/or to other genes that influence Aβ clearance, as for example apoE or clusterin 16 , and interrogate the roles of vascular risk factors, environment and lifestyle. Collectively, our findings suggest that PICALM controls Aβ transport across the BBB and clearance from brain, and is therefore an important therapeutic target for Aβ clearance therapy.
METhODS
Methods and any associated references are available in the online version of the paper. 
